Home  »  Finance   »  This is to seal it as VYNE Therapeutics Inc. (VYNE...

This is to seal it as VYNE Therapeutics Inc. (VYNE) shares are up 92.05% from its 52-week low

VYNE Therapeutics Inc. (VYNE) is priced at $0.21 after the most recent trading session. At the very opening of the session, the stock price was $0.26 and reached a high price of $0.26, prior to closing the session it reached the value of $0.25. The stock touched a low price of $0.209.Recently in News on January 9, 2023, VYNE Therapeutics Announces First Vitiligo Patient Dosed in Phase 1a/b Clinical Trial of Novel BET Inhibitor VYN201. First patient dosed follows swiftly from IND clearance and enrollment of first healthy volunteers in Phase 1a portion of study in November. You can read further details here

VYNE Therapeutics Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $0.3823 on 01/10/23, with the lowest value was $0.1332 for the same time period, recorded on 01/03/23.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…


VYNE Therapeutics Inc. (VYNE) full year performance was -69.15%

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, VYNE Therapeutics Inc. shares are logging -73.09% during the 52-week period from high price, and 92.05% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $0.11 and $0.79.

The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 971409 for the day, which was evidently lower, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the VYNE Therapeutics Inc. (VYNE) recorded performance in the market was 41.73%, having the revenues showcasing -14.99% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 13.01M, as it employees total of 28 workers.

Market experts do have their say about VYNE Therapeutics Inc. (VYNE)

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 0.2362, with a change in the price was noted -0.11. In a similar fashion, VYNE Therapeutics Inc. posted a movement of -34.94% for the period of last 100 days, recording 842,304 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for VYNE is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.

Technical breakdown of VYNE Therapeutics Inc. (VYNE)

Raw Stochastic average of VYNE Therapeutics Inc. in the period of last 50 days is set at 37.52%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 37.52%. In the last 20 days, the company’s Stochastic %K was 48.56% and its Stochastic %D was recorded 53.80%.

Bearing in mind the latest performance of VYNE Therapeutics Inc., several moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 41.73%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -55.32%, alongside a downfall of -69.15% for the period of the last 12 months. The shares increased approximately by -16.17% in the 7-day charts and went down by 25.87% in the period of the last 30 days. Common stock shares were lifted by -14.99% during last recorded quarter.

Leave a Comment

Your email address will not be published. Required fields are marked *

On Key

Related Posts